In June 2024, Defence Therapeutics announced that its second-generation ARM-X anti-cancer vaccine is “therapeutically effective” against pre-established ovarian cancer (ID8 model) in combination with an anti-PD-1 immune-checkpoint inhibitor. Using the Accum platform, Defence previously demonstrated that AccuTOX treatment of MSCs resulted in the induction of antigen cross-presentation capacity (ARM-X cells), which can mount strong anti-tumoral responses in animal pre-clinical models
Accum Technology
Defence suggests that Accum Technology is the first-of-its-kind solution to previous cancer treatment challenges. It has “proven its ability to deliver drugs” to the infected parts of infected cells at “10x the rate” of current solutions by:
- Accumulating more ADCs into a target cell
- Breaking the cell membrane
- Successfully reaching the intercellular target site
- Delivering more of the intended drugs to the intended sites
Defence states that a “major” advantage of the ARM-X vaccine is the lower threshold of antigen quantities to manufacture the vaccine. This “avoids the need of a big tumour sample” in vaccine generation. Sebastian Plouffe, Chief Executive Officer of Defence Therapeutics, emphasises that this is the 4th cancer model to be “efficiently targeted” with the AMR-X anti-cancer vaccine.
“The purpose of testing our vaccine in various models is to highlight how ARM-X can be adapted to the needs of any patient, no matter the type of cancer, given that we have access to a tumour biopsy.”
To participate in discussions about vaccine innovation solutions to the challenges that cancer presents, why not get your tickets to The World Vaccine Congress in Barcelona this October? Don’t forget to subscribe to our weekly newsletters for more insights.
